Cancer Center Amsterdam

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma

Verkleij, C. P. M., O'Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., de Oca, R. M., Zweegman, S., Verona, R. I., Mutis, T. & van de Donk, N. W. C. J., 15 Jul 2024, In: Clinical Cancer Research. 30, 14, p. 3006-3022 17 p.

Research output: Contribution to journal › Article › Academic › peer-review

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Frerichs, K. A., Verkleij, C. P. M., Mateos, M. V., Martin, T. G., Rodriguez, C., Nooka, A., Banerjee, A., Chastain, K., Perales-Puchalt, A., Stephenson, T., Uhlar, C., Kobos, R., van der Holt, B., Kruyswijk, S., Kuipers, M. T., Groen, K., Vishwamitra, D., Skerget, S., Cortes-Selva, D., Doyle, M., & 4 othersZaaijer, H. L., Zweegman, S., Verona, R. I. & van de Donk, N. W. C. J., 9 Jan 2024, In: Blood. 8, 1, p. 194-206 13 p.

Research output: Contribution to journal › Article › Academic › peer-review

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

Hiemstra, I. H., Santegoets, K. C. M., Janmaat, M. L., de Goeij, B. E. C. G., ten Hagen, W., van Dooremalen, S., Boross, P., van den Brakel, J., Bosgra, S., Andringa, G., van Kessel-Welmers, B., Verzijl, D., Hibbert, R. G., Frerichs, K. A., Mutis, T., van de Donk, N. W. C. J., Ahmadi, T., Satijn, D., Sasser, A. K. & Breij, E. C. W., 1 Jul 2023, In: eBioMedicine. 93, 104663.

Research output: Contribution to journal › Article › Academic › peer-review